Global Antiplatelet Drugs Market, by Drug Class (Irreversible Cyclooxygenase (COX) Inhibitors, Adenosine Diphosphate (ADP) Receptor Inhibitors, Glycoprotein IIB/IIIA Inhibitors, Adenosine Reuptake Inhibitors, and Thromboxane Inhibitors and Phosphodiesterase Inhibitors), by Mode of Administration (Oral and Intravenous), by Application (Angioplasty, Arterial Thrombosis, Myocardial Infarction, Percutaneous Coronary Interventions, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 2,153.4 Million in 2022 and is expected to exhibit a CAGR of 7.8% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Increasing launches of new antiplatelet drugs is expected to drive the global antiplatelet drugs market growth over the forecast period. For instance, in November 2020, AstraZeneca plc, a pharmaceutical and biotechnology company, launched new product Brilinta, which contained a new drug for antiplatelet namely ticagrelor had been approved by the U.S. Food and Drug Administration, to reduce the risk of stroke, a leading cause of disability and death worldwide, in patients with acute ischemic stroke (National Institutes of Health Stroke Scale score ≤5) or high-risk transient ischaemic attack (TIA). The approval by the U.S. Food and Drug Administration (FDA) was based on positive results from the THALES Phase III trial, which showed that aspirin plus Brilinta 90mg significantly reduced the rate of the composite of stroke and death compared to aspirin alone in patients with acute ischaemic stroke or TIA.
Global Antiplatelet Drugs Market – Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.
However, the COVID-19 pandemic had a positive impact on the global antiplatelet drugs market, owing to its possible association with the COVID-19 infection. For instance, in December 2020, according to the National Center for Biotechnology Information, the proportion of COVID-19 patients with major cardiovascular risk factors who developed acute arterial thrombosis is higher than that of their non-COVID-19 counterparts. Such finding hinted at the possibility that thromboinflammation played a greater role for the development of arterial thrombosis in COVID-19 patients than traditional cardiovascular risk factors. In addition, the mortality rate of COVID-19 patients with arterial thrombosis was high (44.7%), which indicates a poor prognosis. Therefore, doctors propose routine antiplatelet therapy (low-dose aspirin, clopidogrel, ticagrelor, prasugrel, ticlopidine, and dipyridamole) for arterial thromboprophylaxis in COVID-19 patients who are deemed at heightened risk for the development of acute arterial thrombosis. Low-dose aspirin (75–150mg/d) is sufficient to irreversibly acetylate Ser 530 of COX-1, thus preferentially inhibiting platelet generation of thromboxane A2, and interfering with the formation of arterial thrombus. On the other hand, for P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel, and ticlopidine), either the parent drug or the active metabolite blocks the P2Y12 (adenosine diphosphate receptor) component of adenosine diphosphate receptors on the platelet surface, which prevents activation of the glycoprotein IIb/IIIa receptor complex, thereby reducing platelet aggregation and subsequent arterial thrombus formation.